Interphase fluorescence in situ hybridization (I-FISH) for the BCR-ABL translocation
performed on peripheral blood (PB) white cells has been suggested as a surrogate for …

We describe a method for monitoring chronic myeloid leukemia (CML) patients treated with
imatinib that uses fluorescence in situ hybridization (FISH) to detect BCR-ABL in peripheral …

Imatinib mesylate (trade name Glivec® or Gleevec) is emerging as an important therapy in
the management of chronic myeloid leukaemia (CML). It is clinically useful to monitor the …

Survival among chronic myelogenous leukemia (CML) patients can be linked to the
reduction in leukemic cell burden. Treatment with imatinib mesylate results in a high …

BACKGROUND AND OBJECTIVES: Imatinib is the new standard drug treatment for patients
with chronic myelogenous leukemia (CML). Quantitative reverse transcription-polymerase …

About 75% of patients with newly diagnosed chronic phase (CP) chronic myeloid leukemia
(CML) treated initially with imatinib achieve complete cytogenetic remission (CCyR), 1 and …

Real-time quantitative polymerase chain reaction (PCR) for BCR-ABL mRNA in the
peripheral blood (RQ-PCR) provides an accurate and reliable measure of response to …

For patients with chronic myeloid leukaemia, methods for monitoring response to treatment
have changed considerably in recent years. In the 1980s, the principal approach was …

1Department of Hematology-Oncology" L. and A. Seràgnoli" University of Bologna, Bologna;
2Onco-Hematology Unit, University of Naples Federico II and CEINGE, Biotecnologie …

The degree of tumor load reduction as measured by cytogenetic response is an important
prognostic factor for chronic myelogenous leukemia (CML) patients on therapy. We sought …